Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Ameritas Advisory Services LLC Has $1.16 Million Holdings in Merck & Co., Inc. $MRK
03:29am, Saturday, 14'th Feb 2026
Ameritas Advisory Services LLC trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 52.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutio
Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops
05:35pm, Friday, 13'th Feb 2026
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
11:51am, Friday, 13'th Feb 2026
Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
10:30am, Friday, 13'th Feb 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 13'th Feb 2026
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Stock Market Live February 13, 2026: S&P 500 (SPY) Fighting to Go Green
09:16am, Friday, 13'th Feb 2026
Live Updates Here's why lithium stocks could rocket higher 2 hours ago Live The lithium story is getting explosive - again. For one, lithium remains one of the most strategically important commodities
Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%
12:00pm, Thursday, 12'th Feb 2026
Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing for the f
Barrow, Hanley, Mewhinney & Strauss Makes Significant Move with GE HealthCare Technologies Inc
11:03am, Thursday, 12'th Feb 2026
Insight into the Fourth Quarter 2025 13F Filing Barrow, Hanley, Mewhinney and Strauss (Trades, Portfolio) recently submitted their 13F filing for the fourth quar
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
09:00am, Thursday, 12'th Feb 2026
New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025. KEYTRU
Caprock Group LLC Invests $5.33 Million in Merck & Co., Inc. $MRK
07:14am, Thursday, 12'th Feb 2026
Caprock Group LLC acquired a new stake in Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund ac
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
06:45am, Thursday, 12'th Feb 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium.
Caisse Des Depots ET Consignations Boosts Position in Merck & Co., Inc. $MRK
05:16am, Thursday, 12'th Feb 2026
Caisse Des Depots ET Consignations lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 7.7% in the third quarter, according to the company in its most recent disclosure with the Securi
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab)
Advisors Asset Management Inc. Grows Holdings in Merck & Co., Inc. $MRK
03:34am, Wednesday, 11'th Feb 2026
Advisors Asset Management Inc. lifted its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 14.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 340,309 sha
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
07:39am, Tuesday, 10'th Feb 2026
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
